Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (09.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02. Departure of Directors or Certain Officers, Election of Directors. Two Company dire |
| 07.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ive Agreement The information set forth in Item 5.02 below is hereby incorporated by reference into this Item 1.01. |
| 09.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ive Agreement The information set forth in Item 5.02 below is hereby incorporated by reference into this Item 1.01. |
| 21.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
| 28.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Compensatory Arrangements of Certain Officers On February 23, 2023, the Compensation Committee ( |
| 01.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02– Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Unternehmen & Branche
| Name | IMMUCELL CORP /DE/ |
|---|---|
| Ticker | ICCC |
| CIK | 0000811641 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | 045252306 |
|---|---|
| ISIN | US0452523063 |
| Typ | Common Stock |
| Marktkapitalisierung | 75,8 Mio. USD |
| Beta | 0,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 27,644,174 | -1,040,027 | -0.12 | 42,532,447 | 27,055,480 |
| 2025-09-30 | 10-Q | 5,506,122 | -139,748 | -0.02 | 45,730,123 | 29,800,841 |
| 2025-06-30 | 10-Q | 6,444,880 | 501,880 | 0.06 | 46,720,898 | 29,867,428 |
| 2025-03-31 | 10-Q | 8,067,174 | 1,446,983 | 0.16 | 45,621,579 | 28,993,844 |
| 2024-12-31 | 10-K | 26,493,169 | -2,156,629 | -0.26 | 45,100,477 | 27,518,187 |
| 2024-12-31 | 10-Q | 26,493,169 | 45,100,477 | 27,518,187 | ||
| 2024-09-30 | 10-Q | 6,011,573 | -701,690 | -0.09 | 44,448,873 | 26,411,671 |
| 2024-06-30 | 10-Q | 5,472,890 | -1,531,626 | -0.20 | 41,855,458 | 23,455,463 |
| 2024-03-31 | 10-Q | 7,257,577 | -437,868 | -0.06 | 43,051,048 | 24,636,319 |
| 2023-12-31 | 10-K | 17,471,669 | -5,774,598 | -0.75 | 43,808,102 | 24,993,077 |
| 2023-09-30 | 10-Q | 5,396,500 | -940,000 | -0.12 | 44,545,022 | 26,013,489 |
| 2023-06-30 | 10-Q | -1,379,714 | -0.18 | 44,007,068 | 26,857,055 | |
| 2023-03-31 | 10-Q | -2,315,053 | -0.30 | 43,123,187 | 28,161,112 | |
| 2022-12-31 | 10-K | 18,567,962 | -2,493,805 | -0.32 | 44,860,649 | 30,380,049 |
| 2022-12-31 | 10-Q | 18,567,962 | 44,860,649 | 30,380,049 | ||
| 2022-09-30 | 10-Q | 4,796,025 | -655,078 | -0.08 | 46,401,561 | 31,982,522 |
| 2022-06-30 | 10-Q | -684,148 | -0.09 | 45,983,849 | 32,552,478 | |
| 2022-03-31 | 10-Q | 513,287 | 0.07 | 46,699,496 | 33,150,160 | |
| 2021-12-31 | 10-K | -78,292 | -0.01 | 44,465,688 | 32,576,940 | |
| 2021-12-31 | 10-Q | 19,242,969 | 44,465,688 | 32,576,940 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | te Boekhorst Paul Francis Olivier | Director, Officer, President and CEO | Open Market Purchase | 2,432 | 5.50 | 13,376.49 | +104,9% | |
| 2025-12-03 | te Boekhorst Paul Francis Olivier | Director, Officer, President and CEO | Open Market Purchase | 2,556 | 5.00 | 12,787.67 | +100,3% | |
| 2025-12-03 | te Boekhorst Paul Francis Olivier | Director, Officer, President and CEO | Open Market Purchase | 3,521 | 5.04 | 17,747.95 | +139,2% | |
| 2025-12-03 | te Boekhorst Paul Francis Olivier | Director, Officer, President and CEO | Open Market Purchase | 3,598 | 5.05 | 18,151.91 | +142,4% | |
| 2025-12-02 | te Boekhorst Paul Francis Olivier | Director, Officer, President and CEO | Open Market Purchase | 3,708 | 4.87 | 18,052.77 | +141,6% | |
| 2025-11-25 | Tomsche David Scott | Director | Open Market Purchase | 1,633 | 4.76 | 7,773.08 | +61,0% | |
| 2025-11-25 | Tomsche David Scott | Director | Open Market Purchase | 1,633 | 4.77 | 7,781.25 | +61,0% | |
| 2025-06-12 | Gathagan Bryan K. | Director | Open Market Purchase | 1,000 | 6.32 | 6,320.00 | +49,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.